Gromisch Elizabeth S, Turner Aaron P, Neto Lindsay O, Ruiz Jennifer A, Lo Albert C, Agresta Thomas, Foley Frederick W
Mandell Center for Multiple Sclerosis, Mount Sinai Rehabilitation Hospital, Trinity Health Of New England, Hartford, CT, USA (ESG, LON, JAR, ACL).
Department of Rehabilitative Medicine (ESG, LON, JAR), Frank H. Netter MD School of Medicine at Quinnipiac University, North Haven, CT, USA.
Int J MS Care. 2023 Jan-Feb;25(1):15-19. doi: 10.7224/1537-2073.2021-126. Epub 2022 Sep 7.
The Multiple Sclerosis Resiliency Scale (MSRS) was designed to assess factors connected to resilience when facing MS-related challenges. Although the MSRS has demonstrated good internal consistency and construct validity, its test-retest reliability has yet to be established. Identifying the minimal detectable change (MDC) of the scale will also improve its utility as an outcome measure for resilience-based interventions. This study aimed to determine the test-retest reliability and MDC of the MSRS.
Participants were 62 persons with MS who completed the MSRS twice, with a mean ± SD of 16.60 ± 3.97 days (range, 14-30 days) between assessments. Test-retest reliability was evaluated using a 2-way, random-effects, single-measurement intraclass correlation coefficient (ICC), with agreement between time 1 and time 2 visualized with a Bland-Altman plot. The MDC was calculated using the standard error of measurement with a 95% CI.
At time 1, the mean ± SD MSRS score was 77.19 ± 11.97 (range, 45.83-97.00); at time 2, the mean ± SD score was 76.38 ± 12.75 (range, 46-98). The MSRS total score had good test-retest reliability (ICC = 0.88), with the subscale ICCs ranging from 0.77 (MS Peer Support) to 0.93 (Spirituality). The MDC for the total score was 11.95.
These findings suggest that the MSRS has good test-retest reliability and that persons with MS with a difference of 12 points or more between assessments have experienced a reliable change. The results support the utility of the MSRS as a potential outcome measure for MS-related resilience.
多发性硬化症复原力量表(MSRS)旨在评估面对与多发性硬化症相关挑战时与复原力相关的因素。尽管MSRS已显示出良好的内部一致性和结构效度,但其重测信度尚未确立。确定该量表的最小可检测变化(MDC)也将提高其作为基于复原力干预措施的结果指标的效用。本研究旨在确定MSRS的重测信度和MDC。
62名多发性硬化症患者参与研究,他们两次完成MSRS,两次评估之间的平均间隔时间±标准差为16.60±3.97天(范围为14 - 30天)。使用双向随机效应单测量组内相关系数(ICC)评估重测信度,通过Bland-Altman图直观显示第1次和第2次测量之间的一致性。使用测量标准误和95%置信区间计算MDC。
第1次测量时,MSRS平均得分±标准差为77.19±11.97(范围为45.83 - 97.00);第2次测量时,平均得分±标准差为76.38±12.75(范围为46 - 98)。MSRS总分具有良好的重测信度(ICC = 0.88),各子量表的ICC范围为0.77(MS同伴支持)至0.93(精神性)。总分的MDC为11.95。
这些结果表明MSRS具有良好的重测信度,且评估之间差异达12分或更多的多发性硬化症患者经历了可靠的变化。结果支持MSRS作为多发性硬化症相关复原力潜在结果指标的效用。